A 58-year-old female with a gastric bulging in the greater cur vature/posterior wall [ Figure 1 ] was referred for endoscopic ultrasound (EUS) evaluation. Sectorial EUS (Olympus GF-UCT140-AL5, Olympus America Inc., New York, USA, coupled to an ultrasound unit Aloka Prosound alpha-5SX) detected a well-circumscribed, hypoechoic, and heterogeneous mass in the pancreatic body, with solid and cystic areas, measuring 5 cm × 5 cm [ Figure 2 ]. Main pancreatic duct was not dilated. EUS-guided fine needle aspiration (EUS-FNA) was perfor med via a transgastric approach using a 19-gauge needle (EchoTip Ultra Echo-19, Cook Medical, Winston-Salem, USA) for three passes. A sample of 12 mL of dark-brown liquid was aspirated, as well as tissue cores. There was no on-site cytopathologist. Aspirate was acellular with amylase of 74 U/mL and carcinoembryonic antigen of 5.9 ng/mL. Tissue cores were processed as cell blocks for histologic examination and immunohistochemistry. Histopathology demonstrated a hypercellular tumor with branching papillary arrangements composed of fibrovascular cores and microadenoid structures with cuboidal cells [ Figure 3a ]. Nuclei were round or oval with granular chromatin and small nucleoli. Cytoplasm was granular or vacuolated. No mitotic activity was observed. Tumor cells were negative for periodic-acid Schiff alcian blue. Immunohistochemical stains were positive for beta-catenin (clone B-catenin 1) [ Figure 3b ] and CD10 (clone 56C6) [ Figure 3c ], whereas chromogranin (clone LK2H10) [ Figure 3d ] was negative. These findings confirmed a solid pseudopapillary tumor (SPT) of the pancreas. Tumor was successfully removed, and the patient remains very well so far.
SPT constitutes 1%-2% of all exocrine tumors and 5% of cystic tumors of the pancreas. [1] In the English literature, less than 2800 cases have
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been reported. [2] It occurs in young women in the third decade of life with a frequency of up to 90%. [3, 4] Besides, (pre) malignant pancreatic diseases accounted for 3% of the causes for gastrointestinal bulging [ Table 1] . [5] Symptoms may include abdominal pain and even the presence of a palpable mass. Tumors are usually large and approximately 70% arise in the body and tail of the pancreas. [2, 4] Characteristic imaging findings include an encapsulated lesion with well-defined borders and variable central areas with cystic degeneration, necrosis, or hemorrhage. [2, 4] Differential diagnosis includes a large number of lesions, such as neuroendocrine tumors, acinar cell carcinoma, intraductal papillary mucinous neoplasia, serous cystadenoma, pancreatoblastoma, mucinous cystadenoma, and pseudocysts. Local surgical excision is the treatment for SPT, even for those with local infiltration or distant metastasis. [2, 4] Nadler et al. [6] first made a correct diagnosis of SPT using EUS-FNA in 2002. The diagnostic accuracy of EUS-FNA for SPTs ranges from 69.5% to 82.4%. [2, 7, 8] FNA samples, especially when evaluating cell blocks, demonstrate marked cellularity with pseudopapillae composed of fibrovascular stalks lined with one to several layers of neoplastic cells mixed with discohesive neoplastic cells.
[1] Beta-catenin, CD10, and chromogranin are the most sensitive markers for the diagnosis of SPTs. [9] In conclusion, EUS-FNA provides an accurate preoperative diagnosis, differentiating SPT from other pancreatic neoplasms of similar radiologic appearance but with different biologic behavior and treatment.
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